517 results on '"Rosso, Chiara"'
Search Results
2. A crystal engineering approach for rational design of curcumin crystals for Pickering stabilization of emulsions
3. Impact of PNPLA3 rs738409 Polymorphism on the Development of Liver-Related Events in Patients With Nonalcoholic Fatty Liver Disease
4. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis
5. A nutrigenetic precision approach for the management of Non-alcoholic Fatty Liver Disease
6. WED-243-YI Irisin level as a potential biomarker for hepatic steatosis improvement after a 6-month lifestyle intervention in patients with metabolic dysfunction-associated steatotic liver disease
7. WED-233-YI The single nucleotide polymorphism rs780094 C>T in the glucokinase regulator gene (GCKR) is associated with hepatic steatosis improvement after lifestyle intervention in overweight/obese subjects with metabolic dysfunction-associated steatotic liver disease
8. FRI-243 Echocardiography-based markers of subclinical cardiac dysfunction in patients with MASLD and preserved ejection fraction: prospective data from the Turin cohort
9. FRI-251-YI Hepatic steatosis contributes to cognitive impairment in patients with metabolic dysfunction-associated steatotic liver disease and/or type 2 diabetes-mellitus
10. FRI-314 Plasminogen activator inhibitor-1 (PAI-1) is associated with hepatic steatosis improvement after lifestyle intervention in overweight/obese subjects with metabolic-dysfunction associated steatotic liver disease
11. FRI-230-YI Prevalence and predictors of steatotic liver disease and significant liver fibrosis in an integrated hepatological and nonhepatological healthcare pathway model: preliminary results from a prospective cohort of a tertiary center
12. FRI-479-YI The role of OSM/OSMRβ axis in shaping the immunemicroenvironment favouring MASLD-related HCC immune evasion
13. Rare ATG7 genetic variants predispose patients to severe fatty liver disease
14. Sex‐specific effects of PNPLA3 I148M.
15. Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance
16. Hepatocyte-Specific Deletion of HIF2α Prevents NASH-Related Liver Carcinogenesis by Decreasing Cancer Cell Proliferation
17. The hepatitis D virus in Italy. A vanishing infection, not yet a vanished disease
18. Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease
19. A Healthful Plant-Based Diet as an Alternative Dietary Approach in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease.
20. Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection
21. Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease
22. Molecular Mechanisms of Curcumin in the Pathogenesis of Metabolic Dysfunction Associated Steatotic Liver Disease
23. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease
24. Myostatin regulates the fibrogenic phenotype of hepatic stellate cells via c-jun N-terminal kinase activation
25. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis
26. Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis.
27. Impact of Health Related QoL and Mediterranean Diet on Liver Fibrosis in Patients with NAFLD
28. Prognostic value of simple non-invasive tests for the risk stratification of HCC development in patients with cirrhosis due to non-alcoholic fatty liver disease
29. Thrombospondin-2 as a new biomarker for at risk NASH and advanced fibrosis in a large multicentric European cohort
30. A prospective multicenter study to examine the impact of acquired and genetic predictors on Hepatocellular carcinoma risk in patients with advanced NAFLD: first report
31. De novo lipogenesis discriminates advanced hepatic fibrosis after an oral glucose load in non-obese subjects with non-alcoholic fatty liver disease
32. Glucose and lipid metabolism alterations after an oral lipid meal in patients with non-alcoholic fatty liver disease carrying the PNPLA3 rs738409 polymorphism
33. Impact of PNPLA3 rs738409 single nucleotide polymorphism and carbohydrate intake for the personalized management of patients with non-alcoholic fatty liver disease
34. Interferon gamma-induced protein 10 levels increase across the spectrum of liver disease and are associated with insuline resistant components in subjects with non-alcoholic fatty liver disease
35. Influence of chronotype and adherence to the mediterranean diet on the risk of liver fibrosis in patients with non-alcoholic fatty liver disease
36. Echocardiography-based markers for subclinical cardiac dysfunction in patients with non-alcoholic fatty liver disease and significant fibrosis with preserved ejection fraction: preliminary data from a prospective monocentric Italian cohort
37. Oncostatin M promotes a pro-tumorigenic inflammatory response in NASH-related HCC
38. AGILE 3+ and AGILE 4 scores for the diagnosis of advanced fibrosis and cirrhosis in patients with non-alcoholic fatty liver disease
39. Impact of PNPLA3 rs738409 polymorphism on the development of liver-related events in patients with non-alcoholic fatty liver disease
40. Prognostic Value of Simple Non-Invasive Tests for the Risk Stratification of Incident Hepatocellular Carcinoma in Cirrhotic Individuals with Non-Alcoholic Fatty Liver Disease
41. Prebiotics targeting gut-liver axis to treat non-alcoholic fatty liver disease
42. Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study
43. Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis
44. NAMPT and NAPRT serum levels predict response to anti-TNF therapy in inflammatory bowel disease
45. Cross-Sectional and Longitudinal Performance of Non-Invasive Tests of Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease
46. The Predictive Role of Extracellular NAPRT for the Detection of Advanced Fibrosis in Biopsy-Proven Non-Alcoholic Fatty Liver Disease
47. Identification of the Best Cut-Off Value of PIVKA-II for the Surveillance of Patients at Risk of Hepatocellular Carcinoma Development
48. Higher Hepatic Glucose Production and Gluconeogenesis are Features of Severe Metabolic Dysfunction-Associated Steatohepatitis Even in Absence of T2D
49. Serum glypican-3 for the prediction of survival in patients with hepatocellular carcinoma
50. Impact of Health Related QoL and Mediterranean Diet on Liver Fibrosis in Patients with NAFLD
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.